Matching trials
2,411 results
- Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: Complete Statistical AnalysisIndependent statistical analysis of Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: primary endpoint results, effect estimate with confidence interval,…
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: primary endpoint results, effect estimate with confidence interval,…
- Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- OPERA IIIndependent statistical analysis of OPERA II, a phase 2 single-group study of long-term treatment with PF-00547659 in Crohn's Disease, including its design, adverse-event endpoint, statistical interpretation, and limitations.
- OPERA IIIndependent statistical analysis of A Study To Monitor Long-Term Treatment With PF-00547659: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01298492).
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…
- Opt-INIndependent statistical analysis of Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01814072).
- Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease: Complete Statistical AnalysisIndependent statistical analysis of Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression: Complete Statistical AnalysisIndependent statistical analysis of Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- Oral Calcitriol With Ketoconazole in CRPC: Complete Statistical AnalysisIndependent statistical analysis of Oral Calcitriol With Ketoconazole in CRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03261336).
- Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD): Complete Statistical AnalysisIndependent statistical analysis of Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03028350).
- Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): Complete Statistical AnalysisIndependent statistical analysis of Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia: Complete Statistical AnalysisIndependent statistical analysis of Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409041).
- Oral OKT3 for the Treatment of Active Ulcerative Colitis: Complete Statistical AnalysisIndependent statistical analysis of Oral OKT3 for the Treatment of Active Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01287195).
- Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma: Complete Statistical AnalysisIndependent statistical analysis of Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00301418).
- Oral Testosterone for the Treatment of Hypogonadism: Complete Statistical AnalysisIndependent statistical analysis of Oral Testosterone for the Treatment of Hypogonadism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01717768).
- ORCA-V1Independent statistical analysis of A Study of Cytisinicline for Vaping Cessation in Adult Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05431387).
- Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705): Complete Statistical AnalysisIndependent statistical analysis of Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ORIENT-1Independent statistical analysis of Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ORIGAMAIndependent statistical analysis of Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ORKAIndependent statistical analysis of Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01866423).
- orvepitant MDDIndependent statistical analysis of A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder: primary endpoint results, effect estimate with confidence…
- Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation: Complete Statistical AnalysisIndependent statistical analysis of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03414814).
- OSKIRA-Asia-1Independent statistical analysis of Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- OsteosarcomaIndependent statistical analysis of Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01336803).
- OTBB2Independent statistical analysis of Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OTO-313 in Subjects With Subjective Tinnitus: Complete Statistical AnalysisIndependent statistical analysis of OTO-313 in Subjects With Subjective Tinnitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03918109).
- OU-SCC-PI-4GIndependent statistical analysis of PARP Inhibition for Gliomas (PI-4G or π4g): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05297864).
- Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter’s Syndrome, Refractory CLL and PLL: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00418093).
- Oxidative Stress in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Oxidative Stress in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04512547).
- OXT-PWSIndependent statistical analysis of Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Oxytocin and Affect Processing in Posttraumatic Stress Disorder: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin and Affect Processing in Posttraumatic Stress Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02546570).
- Oxytocin, Alcohol Craving, and Intimate Partner Aggression: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin, Alcohol Craving, and Intimate Partner Aggression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03046836).
- OZGAMIndependent statistical analysis of Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02431650).
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI): Complete Statistical AnalysisIndependent statistical analysis of P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PACEComplete statistical analysis of the randomized phase 2 PACE trial evaluating palbociclib-based treatment after CDK and endocrine therapy in metastatic breast cancer, including PFS, response, statistical methodology, safety, and interpretation.
- PACIFIC-6Independent statistical analysis of PACIFIC-6 (NCT03693300), a phase 2 study of durvalumab after sequential chemoradiation in patients with unresectable stage III non-small cell lung cancer, focusing on its safety endpoint, exact binomial…